Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 6/20 | 0.65 |
| ▸ | CNR2 | P34972 | 6/20 | 0.65 |
| ▸ | RPA1 | P27694 | 3/20 | 0.58 |
| ▸ | GRN | P28799 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.49 |
| ▸ | BCL2 | P10415 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28287989 | 0.86 | ALDH1A1 (0.76) | ALDH1A1CNR1CNR2RPA1PPP1CA | |
| SCHEMBL3975817 | 0.84 | ALDH1A1 (0.72) | ALDH1A1CNR1CNR2RPA1L3MBTL1 | |
| SCHEMBL1107620 | 0.83 | ALDH1A1 (0.70) | ALDH1A1CNR1CNR2 | |
| SCHEMBL31377474 | 0.82 | ALDH1A1 (0.68) | ALDH1A1CNR1CNR2MEN1KMT2A | |
| SCHEMBL4504962 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CNR1CNR2RPA1L3MBTL1 | |
| SCHEMBL1259296 | 0.78 | ALDH1A1 (0.64) | ALDH1A1RPA1L3MBTL1PPP1CABCL2 | |
| SCHEMBL23401799 | 0.78 | ALDH1A1 (0.64) | ALDH1A1CNR1CNR2GRNSORT1 | |
| SCHEMBL2028916 | 0.78 | ALDH1A1 (0.62) | ALDH1A1CNR1CNR2MCL1 | |
| SCHEMBL1143854 | 0.78 | RPA1 (0.67) | ALDH1A1RPA1L3MBTL1PPP1CABCL2 | |
| SCHEMBL18358776 | 0.77 | ALDH1A1 (0.61) | ALDH1A1CNR1CNR2RPA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008141358-A1 | FRAGMENTATION PROFILE BASED AUTHENTIFICATION OF PROTEIN SOURCE | PROTEOMICS INTERNATIONAL PTY LTD (AU) | 2008-11-27 | — | — | WO | claimed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008130322-A1 | NOVEL 5-HETEROCYCLYL-CHROMANE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | ALDH1A1 1426/4885CNR1 1740/4885CNR2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.